Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-05-14

Clinical Trial Update: Gan & Lee Insulin Glargine Target Type (1) Evaluating Research [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating insulin glargine for Type 1 diabetes completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Insulin glargine (Gan & Lee) (insulin glargine)

Snippet

Sponsor: Gan and Lee Pharmaceuticals, USA | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2024-05-14